Love Your Hair Color? You Have 100 Genes to Thank

The researchers who pinpointed the origins of hair hue said their findings could improve understanding of health conditions linked to pigmentation, including skin, testicular, prostate and ovarian cancers.
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 18 January 2019Source: Inorganic Chemistry CommunicationsAuthor(s): Yi-Dong Bin, Yan Yang, Xu-Jian Luo, Hua-Xin ZhangAbstractA novel Pt(II) complex of [PtII(MPP)(OPD)]Cl⋅H2O (MPP-Pt) (OPD = o-phenylenediamine) with 2-(2,5-methoxy-phenyl) imidazo [4,5-f]-[1, 10] phenanthrolin (H-MPP) was synthesized and fully characterized. In MPP-Pt complex, the Pt(II) ion adopts a four-coordinated square planar geometry. MPP-Pt exhibited selective cytotoxicity against human carcinoma (A549), hepatoblastoma (Hep-G2), ovarian (SK-OV-3), cervical (HeLa) and gastric adenocarcinoma (MGC80–3) ce...
Source: Inorganic Chemistry Communications - Category: Chemistry Source Type: research
Condition:   Ovarian Cancer Intervention:   Diagnostic Test: Ultrasound, CT and WB-DWI/MRI Sponsor:   Charles University, Czech Republic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: Our results suggested that familial risks for colon cancer were higher than risks for rectal cancer in families of patients with colorectal cancer and colon cancer. The relationships of lung cancer and nervous system cancer with colorectal cancer were site specific. The associations of colon and rectal cancers with lung cancer, myeloma, and cancer of unknown primary appeared not to point out known syndromes and may suggest involvement of a novel predisposition. See Video Abstract at http://links.lww.com/DCR/A791.
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions Source Type: research
This study included 21 patients diagnosed with brain metastasis from EOC between 1999 and 2009.Results: Median age was 61 years (range 38-77). The median time elapsed from EOC diagnosis to brain metastasis detection was 32 months. Single brain metastases were found in 10 (48%) cases, and there was extra-cranial disease in 11 (52%) cases. During the mean 86 months of follow-up, 18 of the patients (86%) died of the disease and 3 (14%) were alive with disease. The median survival time after the initial diagnosis of brain metastasis was 9 months. The median overall survival (OS) from initial diagnosis of EOC was 50 months. In ...
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, Zhang ZY, Hanke J, Ramaswamy S, Wang J Abstract Niraparib is an orally bioavailable and selective poly (ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of both BRCA mutant (mut) and BRCA wildtype (wt) adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers who have demonstrated a complete or partial response to platinum-based chemotherapy. In patients without germline BRCA mutations (non-gBRCAmut), niraparib improved progression-free survival (PFS) by 5.4 months, whereas another...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer, Published online: 17 January 2019; doi:10.1038/s41416-018-0349-6Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Condition:   Ovarian Cancer Interventions:   Drug: Niraparib;   Drug: Bevacizumab;   Drug: TSR042;   Drug: Carboplatin;   Drug: Paclitaxel Sponsor:   Nordic Society for Gynaecologic Oncology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 16 January 2019Source: Journal of Trace Elements in Medicine and BiologyAuthor(s): Aydan Caglayan, Doruk Cevdi Katlan, Zafer Selcuk Tuncer, Kunter YüceAbstractEpithelial ovarian cancer (EOC) has been associated with oxidative stress (OS) due to epithelial inflammation which makes ovaries more vulnerable to the deleterious effects of reactive oxygen species (ROS). However, antioxidant enzymes (AOEs) such as manganese-superoxide dismutase (Mn-SOD), copper,zinc-superoxide dismutase (Cu,Zn-SOD) and glutathione peroxidase (GPx1) protect cells against the biological damage of ROS-induced O...
Source: Journal of Trace Elements in Medicine and Biology - Category: Biochemistry Source Type: research
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00836
Source: Molecular Pharmaceutics - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSIONS: This study demonstrates the ability of [18F]FSPG to detect upregulated antioxidant pathways present in drug-resistant cancer. [18F]FSPG may therefore enable the identification of HGSOC patients that are refractory to standard-of-care, allowing the transferral of drug-resistant patients to alternative therapies, thereby improving outcomes in this disease. PMID: 30651275 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Health | Ovarian Cancer | Ovaries | Skin